The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
Open accessAbstract
Cancer cells have metabolic dependencies that distinguish them from their normal counterparts. Among these dependencies is an increased use of the amino acid glutamine to fuel anabolic processes. Indeed, the spectrum of glutamine-dependent tumours and the mechanisms whereby glutamine supports cancer metabolism remain areas of active investigation. Here we report the identification of a non-canonical pathway of glutamine use in human pancreatic ductal adenocarcinoma (PDAC) cells that is required for tumour growth. Whereas most cells use glutamate dehydrogenase (GLUD1) to convert glutamine-derived glutamate into α-ketoglutarate in the mitochondria to fuel the tricarboxylic acid cycle, PDAC relies on a distinct pathway in which glutamine-derived aspartate is transported into the cytoplasm where it can be converted into oxaloacetate by aspartate transaminase (GOT1). Subsequently, this oxaloacetate is converted into malate and then pyruvate, ostensibly increasing the NADPH/NADP(+) ratio which can potentially maintain the cellular redox state. Importantly, PDAC cells are strongly dependent on this series of reactions, as glutamine deprivation or genetic inhibition of any enzyme in this pathway leads to an increase in reactive oxygen species and a reduction in reduced glutathione. Moreover, knockdown of any component enzyme in this series of reactions also results in a pronounced suppression of PDAC growth in vitro and in vivo. Furthermore, we establish that the reprogramming of glutamine metabolism is mediated by oncogenic KRAS, the signature genetic alteration in PDAC, through the transcriptional upregulation and repression of key metabolic enzymes in this pathway. The essentiality of this pathway in PDAC and the fact that it is dispensable in normal cells may provide novel therapeutic approaches to treat these refractory tumours.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, depending on the tissue of origin, cancer cells use various routes of glutamine metabolism. Some have been shown to require an exogenous glutamine supply for malignant proliferation [71,72], whereas others do not [73] and can synthesize it de novo [74].”
From HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells (2021) · cites this paper as [73]
In the citing paper
“For instance, KRAS-dependent upregulation of Glutamate Oxaloacetate Transaminase 1,2. (GOT) expression in pancreatic cancer facilitates production of aspartate for nucleotide biosynthesis, and allows NADPH generation via ME157,58 (Fig 2).”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [57]
In the citing paper
“Mouse PDAC tumors driven by mutant Kras also experience metabolic alteration and are dependent on glucose and glutamine (73, 77).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [77]
In the citing paper
“combining inhibition of glycolysis with blockade of KRAS effector signaling pathways has shown efficacy in culture and xenograft models197”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [197]
In the citing paper
“metabolic inhibition approaches combined with RAS pathway inhibitors have shown strong pre-clinical data and are currently in clinical trials197,224,225”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [197]
In the citing paper
“However, under normal and glucose-replete conditions, transamination is the dominant reaction that drives glutamine anaplerosis in cultured cells (79, 80, 81, 82).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [81]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Self-citationSpencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate
Ward, P. S., & Thompson, C. B. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.014 · Cited by 3,233
DeBerardinis, R. J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff, M., Wehrli, S., & Thompson, C. B. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709747104 · Cited by 2,622
Hidalgo, M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0901557 · Cited by 2,570
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S., et al. (2011) · Nature · doi:10.1038/nature10189 · Cited by 2,277
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
Self-citationWise, D. R., DeBerardinis, R. J., Mancuso, A., Sayed, N., Zhang, X.-Y., Pfeiffer, H. K., Nissim, I., Daikhin, E., Yudkoff, M., McMahon, S. B., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810199105 · Cited by 2,001
Glutamine addiction: a new therapeutic target in cancer
Wise, D. R., & Thompson, C. B. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.05.003 · Cited by 1,770
Cited by
Sorted by citations
Items 701–800 of 1,004
Novel Therapeutic Targets of Tumor Metabolism
Kishton, R. J., & Rathmell, J. C. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000099 · Cited by 48
Nault, R., Fader, K. A., Kirby, M. P., Ahmed, S., Matthews, J. B., Jones, A. D., Lunt, S. Y., & Zacharewski, T. R. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfv245 · Cited by 51
Biosynthetic energy cost for amino acids decreases in cancer evolution
Zhang, H., Wang, Y., Li, J., Chen, H., He, X., Zhang, H., Liang, H., & Lü, J. (2018) · Nature Communications · doi:10.1038/s41467-018-06461-1 · Cited by 49
Targeting the Metabolic Rewiring in Pancreatic Cancer and Its Tumor Microenvironment
Yamamoto, K., Iwadate, D., Kato, H., Nakai, Y., Tateishi, K., & Fujishiro, M. (2022) · Cancers · doi:10.3390/cancers14184351 · Cited by 52
Song, J. H., An, N., Chatterjee, S., Kistner‐Griffin, E., Mahajan, S., Mehrotra, S., & Kraft, A. S. (2014) · Oncogene · doi:10.1038/onc.2014.306 · Cited by 46
Glutamine at focus: versatile roles in cancer
Vitto, H. D., Pérez-Valencia, J. A., & Radosevich, J. A. (2015) · Tumor Biology · doi:10.1007/s13277-015-4671-9 · Cited by 54
Structural basis for exploring the allosteric inhibition of human kidney type glutaminase
Ramachandran, S., Pan, C. Q., Zimmermann, S. C., Duvall, B. R., Tsukamoto, T., Low, B. C., & Sivaraman, J. (2016) · Oncotarget · doi:10.18632/oncotarget.10791 · Cited by 51
Wang, D., Meng, G., Zheng, M., Zhang, Y., Chen, A., Wu, J., & Wei, J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166423 · Cited by 48
Oba, D., Inoue, S., Miyagawa‐Tomita, S., Nakashima, Y., Niihori, T., Yamaguchi, S., Matsubara, Y., & Aoki, Y. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.11.029 · Cited by 48
Parzych, K., Saavedra-García, P., Valbuena, G. N., Al-Sadah, H. A., Robinson, M. E., Penfold, L., Kuzeva, D. M., Ruiz-Tellez, A., Loaiza, S., Holzmann, V., et al. (2019) · Oncogene · doi:10.1038/s41388-018-0651-z · Cited by 51
Three-Dimensional Graphene Enhances Neural Stem Cell Proliferation Through Metabolic Regulation
Fang, Q., Zhang, Y., Chen, X., Li, H., Cheng, L., Zhu, W., Zhang, Z., Tang, M., Liu, W., Wang, H., et al. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00436 · Cited by 48
Helenius, I. T., Madala, H. R., & Yeh, J.-R. J. (2021) · Biomolecules · doi:10.3390/biom11111666 · Cited by 43
Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints
Xu, Y., He, L., Fu, Q., & Hu, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.759015 · Cited by 51
Xia, M., Li, X., Diao, Y., Du, B., & Li, Y. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100920 · Cited by 48
Prevention and treatment of cancers by immune modulating nutrients
Janakiram, N. B., Mohammed, A., Madka, V., Kumar, G., & Rao, C. V. (2016) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201500884 · Cited by 48
Metabolomics in pancreatic cancer biomarkers research
Tumas, J., Kvederavičiūtė, K., Petrulionis, M., Kurlinkus, B., Rimkus, A., Sakalauskaitė, G., Cicenas, J., & Šileikis, A. (2016) · Medical Oncology · doi:10.1007/s12032-016-0853-6 · Cited by 46
Energy metabolism in skin cancers: A therapeutic perspective
Hosseini, M., Kasraian, Z., & Rezvani, H. R. (2017) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2017.01.013 · Cited by 46
Craveiro, M., Cretenet, G., Mongellaz, C., Matias, M. I., Caron, O., de Lima, M. C. P., Zimmermann, V. S., Solary, É., Dardalhon, V., Dulić, V., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aal3024 · Cited by 48
Emerging functions of the nuclear receptor LRH-1 in liver physiology and pathology
Sun, Y., Demagny, H., & Schoonjans, K. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166145 · Cited by 45
Glutamine metabolism: from proliferating cells to cardiomyocytes
Shen, Y., Zhang, Y., Li, W., Chen, K., Xiang, M., & Ma, H. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154778 · Cited by 44
Nutrient transporters: connecting cancer metabolism to therapeutic opportunities
Nwosu, Z. C., Song, M. G., di Magliano, M. P., Lyssiotis, C. A., & Kim, S. E. (2023) · Oncogene · doi:10.1038/s41388-023-02593-x · Cited by 51
Self-citationResearch into cancer metabolomics: Towards a clinical metamorphosis
Olivares, O., Däbritz, J. H. M., King, A., Gottlieb, E., & Halsey, C. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.09.008 · Cited by 45
Koufaris, C., & Nilsson, R. (2018) · Cancer & Metabolism · doi:10.1186/s40170-018-0185-4 · Cited by 45
Jiang, Z., Lu, M., & You, Q. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01121 · Cited by 45
Shan, M., Dai, D. L., Vudem, A., Varner, J. D., & Stroock, A. D. (2018) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006584 · Cited by 47
Topotecan induces apoptosis via ASCT2 mediated oxidative stress in gastric cancer
Wang, L., Liu, Y., Zhao, T., Li, Z., He, J., Zhang, B.-J., Du, H., Jiang, J., Yuan, S., & Sun, L. (2018) · Phytomedicine · doi:10.1016/j.phymed.2018.12.011 · Cited by 45
Mitophagy and Oxidative Stress in Cancer and Aging: Focus on Sirtuins and Nanomaterials
Vernucci, E., Tomino, C., Molinari, F., Limongi, D., Aventaggiato, M., Sansone, L., Tafani, M., & Russo, M. A. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/6387357 · Cited by 43
Ramirez‐Peña, E., Arnold, J. M., Shivakumar, V., Joseph, R., Vijay, G. V., den Hollander, P., Bhangre, N., Allegakoen, P., Prasad, R., Conley, Z. C., et al. (2019) · Cancers · doi:10.3390/cancers11101610 · Cited by 46
The Metabolic Interplay between Cancer and Other Diseases
Le, A., Udupa, S., & Zhang, C. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.10.012 · Cited by 48
Wang, W., Pan, H., Ren, F., Chen, H., & Ren, P. (2022) · Bioscience Reports · doi:10.1042/bsr20212171 · Cited by 44
Discovery of decreased ferroptosis in male colorectal cancer patients with KRAS mutations
Yan, H. Y., Talty, R., Jain, A., Cai, Y. A., Zheng, J., Shen, X., Muca, E., Paty, P. B., Bosenberg, M., Khan, S. A., et al. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102699 · Cited by 44
Glutamine Metabolism: Molecular Regulation, Biological Functions, and Diseases
Kumar, M. A., Baba, S. K., Khan, I. R., Khan, M. S., Husain, F. M., Ahmad, S., Haris, M., Singh, M., Akil, A. A., Macha, M. A., et al. (2025) · MedComm · doi:10.1002/mco2.70120 · Cited by 52
Pancreatic cancer: molecular pathogenesis and emerging therapeutic strategies
Rozengurt, E., & Eibl, G. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02499-y · Cited by 49
Follia, L., Ferrero, G., Mandili, G., Beccuti, M., Giordano, D., Spadi, R., Satolli, M. A., Evangelista, A., Katayama, H., Hong, W., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00115 · Cited by 44
Roca, M. S., Moccia, T., Iannelli, F., Testa, C., Vitagliano, C., Minopoli, M., Camerlingo, R., Riso, G. D., Cecio, R. D., Bruzzese, F., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02295-4 · Cited by 44
Wetzel, T. J., Erfan, S. C., Figueroa, L. D., Wheeler, L. M., & Ananieva, E. A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1186539 · Cited by 44
Polyamines: the pivotal amines in influencing the tumor microenvironment
Holbert, C. E., Casero, R. A., & Stewart, T. M. (2024) · Discover Oncology · doi:10.1007/s12672-024-01034-9 · Cited by 46
TP63 and TP73 in cancer, an unresolved “family” puzzle of complexity, redundancy and hierarchy
Costanzo, A., Pediconi, N., Narcisi, A., Guerrieri, F., Belloni, L., Fausti, F., Botti, E., & Levrero, M. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.06.047 · Cited by 43
Sanders, E. B., & Diehl, S. (2015) · Oncoscience · doi:10.18632/oncoscience.128 · Cited by 43
Cetinbas, N. M., Sudderth, J., Harris, R. C., Cebeci, A., Negri, G. L., Yilmaz, Ö. H., DeBerardinis, R. J., & Sorensen, P. H. B. (2016) · Scientific Reports · doi:10.1038/srep32606 · Cited by 45
NRF2 Rewires Cellular Metabolism to Support the Antioxidant Response
Lin, T.-Y., Cantley, L. C., & DeNicola, G. M. (2016) · InTech eBooks · doi:10.5772/65141 · Cited by 48
Self-citationMUC1 facilitates metabolomic reprogramming in triple-negative breast cancer
Goode, G. D., Gunda, V., Chaika, N. V., Purohit, V., Yu, F., & Singh, P. K. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176820 · Cited by 43
Cho, Y.-R., Lee, J. H., Kim, J. H., Lee, S., Yoo, S., Jung, M., Kim, S. J., Yoo, H. J., Pack, C.-G., Rho, J. K., et al. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12324 · Cited by 42
Self-citationBachet, J., Blons, H., Hammel, P. R., Hariry, I. E., Portales, F., Mineur, L., Metges, J., Mulot, C., Bourreau, C., Cain, J. E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0950 · Cited by 43
Zhang, L., & Tew, K. D. (2021) · Advances in cancer research · doi:10.1016/bs.acr.2021.03.009 · Cited by 43
Ma, G., Li, C., Zhang, Z., Liang, Y., Liang, Z., Chen, Y., Wang, L., Li, D., Zeng, M., Shan, W., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.697894 · Cited by 45
Dual Inhibitions on Glucose/Glutamine Metabolisms for Nontoxic Pancreatic Cancer Therapy
Xu, Y., Yu, Z., Fu, H., Guo, Y., Hu, P., & Shi, J. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c00111 · Cited by 43
Kaira, K., Sunose, Y., Arakawa, K., Sunaga, N., Shimizu, K., Tominaga, H., Oriuchi, N., Nagamori, S., Kanai, Y., Oyama, T., et al. (2014) · Histopathology · doi:10.1111/his.12464 · Cited by 43
Anglin, J., Zavareh, R. B., Sander, P. N., Haldar, D., Mullarky, E., Cantley, L. C., Kimmelman, A. C., Lyssiotis, C. A., & Lairson, L. L. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.04.061 · Cited by 39
Self-citationRestall, I. J., Cseh, O., Richards, L. M., Pugh, T. J., Luchman, H. A., & Weiss, S. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3923 · Cited by 42
Zhu, T., Cen, Y., Chen, Z., Zhang, Y., Zhao, L., Wang, J., Lü, W., Xie, X., & Wang, X. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04943-1 · Cited by 44
Self-citationGlutamine metabolism in cancers: Targeting the oxidative homeostasis
Gong, T., Zheng, C., Ou, X., Zheng, J., Yu, J., Chen, S., Duan, Y., & Liu, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.994672 · Cited by 45
Bioinspired Lipid Nanocarriers for RNA Delivery
Golubovic, A., Tsai, S., & Li, B. (2023) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.2c00073 · Cited by 49
AKT1 phosphorylation of cytoplasmic ME2 induces a metabolic switch to glycolysis for tumorigenesis
Chen, T., Xie, S., Cheng, J., Zhao, Q. L., Wu, H., Jiang, P., & Du, W. (2024) · Nature Communications · doi:10.1038/s41467-024-44772-8 · Cited by 42
Pancreatic Cancer: “A Riddle Wrapped in a Mystery inside an Enigma”
Borazanci, E. H., Dang, C. V., Robey, R. W., Bates, S. E., Chabot, J. A., & Hoff, D. D. V. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2070 · Cited by 42
Caiola, E., Falcetta, F., Giordano, S., Marabese, M., Garassino, M. C., Broggini, M., Pastorelli, R., & Brunelli, L. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0954-5 · Cited by 41
Song, M., Ou, F., Zemla, T., Hull, M. A., Shi, Q., Limburg, P. J., Alberts, S. R., Sinicrope, F. A., Giovannucci, E. L., Blarigan, E. L. V., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32113 · Cited by 42
Varshavi, D., Varshavi, D., McCarthy, N., Veselkov, K., Keun, H. C., & Everett, J. R. (2020) · Metabolomics · doi:10.1007/s11306-020-01674-2 · Cited by 41
NADK is activated by oncogenic signaling to sustain pancreatic ductal adenocarcinoma
Schild, T., McReynolds, M. R., Shea, C., Low, V., Schaffer, B. E., Asara, J. M., Piskounova, E., Dephoure, N., Rabinowitz, J. D., Gomes, A. P., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109238 · Cited by 42
Self-citationTargeting fuel pocket of cancer cell metabolism: A focus on glutaminolysis
Sharma, S., Agnihotri, N., & Kumar, S. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.114943 · Cited by 42
Gorgoglione, R., Impedovo, V., Riley, C. L., Fratantonio, D., Tiziani, S., Palmieri, L., Dolce, V., & Fiermonte, G. (2022) · Cancers · doi:10.3390/cancers14010245 · Cited by 44
Increased glucose availability sensitizes pancreatic cancer to chemotherapy
Gohar, A. V., Hue, J. J., Abbas, A., Graor, H. J., Hajihassani, O., Zarei, M., Titomihelakis, G., Feczko, J., Rathore, M. G., Chełstowska, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38921-8 · Cited by 45
Self-citationTargeting succinylation-mediated metabolic reprogramming as a potential approach for cancer therapy
Liu, Z., Wang, R., Wang, Y., Duan, Y., & Zhan, H. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115713 · Cited by 43
Energy sensing and cancer: LKB1 function and lessons learnt from Peutz–Jeghers syndrome
Shorning, B. Y., & Clarke, A. R. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.02.015 · Cited by 45
ZSCAN10 expression corrects the genomic instability of iPSCs from aged donors
Skamagki, M., Correia, C., Yeung, P. L., Baslan, T., Beck, S. J., Zhang, C., Ross, C. A., Dang, L., Liu, Z., Giunta, S., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3598 · Cited by 40
Systematic analyses of glutamine and glutamate metabolisms across different cancer types
Tian, Y., Du, W., Cao, S., Wu, Y., Dong, N., Wang, Y., & Xu, Y. (2017) · 癌症：英文版 · doi:10.1186/s40880-017-0255-y · Cited by 41
Repurposing metformin for the treatment of gastrointestinal cancer
Júnior, A. D. D. C., Bragagnoli, A. S. C., Costa, F. O., & Carvalheira, J. B. C. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i17.1883 · Cited by 42
Johnson, R. L., Cummings, M., Thangavelu, A., Theophilou, G., Jong, D. D., & Orsi, N. M. (2021) · Cancers · doi:10.3390/cancers13246231 · Cited by 39
Raghavan, K. S., Francescone, R., Franco-Barraza, J., Gardiner, J. C., Vendramini-Costa, D. B., Luong, T., Pourmandi, N., Andren, A., Kurimchak, A., Ogier, C., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-21-0147 · Cited by 40
Self-citationLipid metabolism in tumor microenvironment: novel therapeutic targets
Liu, X., Zhang, P., Xu, J., Lv, G., & Li, Y. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02645-4 · Cited by 39
Inhibitors of glucose transport and glycolysis as novel anticancer therapeutics
Qian, Y. (2014) · World Journal of Translational Medicine · doi:10.5528/wjtm.v3.i2.37 · Cited by 41
Endogenous glutamine decrease is associated with pancreatic cancer progression
Roux, C., Riganti, C., Borgogno, S. F., Curto, R., Curcio, C., Catanzaro, V., Digilio, G., Padovan, S., Puccinelli, M. P., Isabello, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20545 · Cited by 40
MDH1 and MPP7 Regulate Autophagy in Pancreatic Ductal Adenocarcinoma
New, M. I., Acker, T. V., Sakamaki, J.-I., Jiang, M., Saunders, R. E., Long, J. S., Wang, V. M.-Y., Behrens, A., Cerveira, J., Sudhakar, P., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2553 · Cited by 41
Metabolic Reprogramming of Cancer by Chemicals that Target Glutaminase Isoenzymes
Matés, J. M., Campos-Sandoval, J. A., Santos-Jiménez, J. D. L., Segura, J. A., Alonso, F. J., & Márquez, J. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190416165004 · Cited by 41
Jia, C., Li, H., Fu, D., & Lan, Y. (2020) · BioMed Research International · doi:10.1155/2020/1921609 · Cited by 42
Cytosolic ME1 integrated with mitochondrial IDH2 supports tumor growth and metastasis
Shao, C., Lu, W., Du, Y., Yan, W., Bao, Q., Tian, Y., Wang, G., Ye, H., & Hao, H. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101685 · Cited by 41
Sun, H.-W., Wu, W., Chen, H., Xu, Y.-T., Yang, Y., Chen, J., Yu, X.-J., Wang, Z., Shuang, Z., & Zheng, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.616367 · Cited by 40
Han, X., Fang, Y., Chen, P., Xu, Y., Zhou, W., Rong, Y., Li, J., Chen, W., & Lou, W. (2021) · Cell Cycle · doi:10.1080/15384101.2021.1874684 · Cited by 40
Malic enzyme 2 maintains protein stability of mutant p53 through 2-hydroxyglutarate
Zhao, M., Yao, P., Mao, Y., Wu, J., Wang, W., Geng, C., Cheng, J., Du, W., & Jiang, P. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00532-w · Cited by 40
Wang, Y., Chen, F., Zhou, H., Huang, L., Ye, J., Liu, X., Sheng, W., Gao, W., Yu, H., & Wang, F. (2022) · Small Methods · doi:10.1002/smtd.202200888 · Cited by 41
Döppler, H. R., & Störz, P. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00041 · Cited by 40
NO•/RUNX3/kynurenine metabolic signaling enhances disease aggressiveness in pancreatic cancer
Wang, L., Tang, W., Yang, S., He, P., Wang, J., Gaedcke, J., Ströbel, P., Azizian, A., Ried, T., Gaida, M. M., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.32733 · Cited by 37
Fan, Y., Xue, H., Li, Z., Huo, M., Gao, H., & Guan, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1345522 · Cited by 40
Metabolic Adaptation-Mediated Cancer Survival and Progression in Oxidative Stress
Tang, Y., Zhang, Z., Chen, Y., Qin, S., Zhou, L., Gao, W., & Shen, Z. (2022) · Antioxidants · doi:10.3390/antiox11071324 · Cited by 47
Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies
Turpin, A., Neuzillet, C., Colle, E., Dusetti, N., Nicolle, R., Cros, J. F., de Mestier, L., Bachet, J., & Hammel, P. R. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221118019 · Cited by 41
Associations between genetically predicted levels of blood metabolites and pancreatic cancer risk
Zhong, H., Liu, S., Zhu, J., & Wu, L. (2023) · International Journal of Cancer · doi:10.1002/ijc.34466 · Cited by 40
Amino acid metabolism in tumor: New shine in the fog?
Qiu, H., Shao, N., Liu, J., Zhao, J.-J., Chen, C., Li, Q., He, Z., Zhao, X., & Xu, L. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2023.06.011 · Cited by 38
Phytochemicals Target Multiple Metabolic Pathways in Cancer
Shuvalov, O. Y., Kirdeeva, Y., Daks, A. A., Fedorova, O., Parfenyev, S. E., Simon, H., & Barlev, N. A. (2023) · Antioxidants · doi:10.3390/antiox12112012 · Cited by 43
Cytosolic acetyl-coenzyme A is a signalling metabolite to control mitophagy
Zhang, Y., Shen, X. L., Shen, Y., Wang, C., Yu, C., Han, J., Cao, S., Qian, L., Ma, M., Huang, S., et al. (2025) · Nature · doi:10.1038/s41586-025-09745-x · Cited by 48
Mapping cancer cell metabolism with 13 C flux analysis: Recent progress and future challenges
Young, J., Duckwall, C., & Murphy, T. A. (2013) · Journal of Carcinogenesis · doi:10.4103/1477-3163.115422 · Cited by 43
Targeting Pathways Downstream of KRAS in Lung Adenocarcinoma
Zhu, Z., Golay, H. G., & Barbie, D. A. (2014) · Pharmacogenomics · doi:10.2217/pgs.14.108 · Cited by 40
Wu, Y. S., Looi, C. Y., Subramaniam, K. S., Masamune, A., & Chung, I. (2016) · Oncotarget · doi:10.18632/oncotarget.9165 · Cited by 39
Metabolic plasticity in heterogeneous pancreatic ductal adenocarcinoma
Liang, C., Qin, Y., Zhang, B., Ji, S., Shi, S., Xu, W., Liu, J., Xiang, J., Liang, D., Hu, Q., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.09.001 · Cited by 39
Energy sources identify metabolic phenotypes in pancreatic cancer
Liang, C., Qin, Y., Zhang, B., Ji, S., Shi, S., Xu, W., Liu, J., Xiang, J., Liang, D., Hu, Q., et al. (2016) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmw097 · Cited by 37
Serum metabolomics differentiating pancreatic cancer from new-onset diabetes
He, X., Zhong, J., Wang, S., Zhou, Y., Wang, L., Zhang, Y., & Yuan, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.16249 · Cited by 39
Wen, Z., Jie, J., Zhang, Y., Liu, H., & Peng, L. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.09.132 · Cited by 39
Impairing energy metabolism in solid tumors through agents targeting oncogenic signaling pathways
Fumarola, C., Petronini, P. G., & Alfieri, R. R. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.03.006 · Cited by 38
Metabolic reprogramming dynamics in tumor spheroids: Insights from a multicellular, multiscale model
Roy, M., & Finley, S. D. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007053 · Cited by 39
Metabolic Regulation of Epithelial to Mesenchymal Transition: Implications for Endocrine Cancer
Bhattacharya, D., & Scimè, A. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00773 · Cited by 39
Wang, S., Li, M., Li, Y., He, M., Lin, H., Xu, Y., Wan, Q., Qin, G., Chen, G., Xu, M., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33877 · Cited by 39
Metadata
- Authors
- Son, J., Lyssiotis, C. A., Ying, H., Wang, X., Hua, S., Ligorio, M., Perera, R. M., Ferrone, C. R., Mullarky, E., Shyh-Chang, N., Kang, Y., Fleming, J. B., Bardeesy, N., Asara, J. M., Haigis, M. C., DePinho, R. A., Cantley, L. C., & Kimmelman, A. C.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Beth Israel Deaconess Medical Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Massachusetts General Hospital (US)
- Harvard University (US)
- Corresponding author
- Cantley, Lewis C.
- Kimmelman, Alec C.
- ORCID
- Venue
- Nature
- Published
- 2013-03-27
- Volume
- 496
- Issue
- 7443
- Pages
- 101-105
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3656466
- OpenAlex
- W2014988241
- Cited by
- 1,990
- References
- 27
- Citations by year
- 2026: 130 · 2025: 143 · 2024: 138 · 2023: 169 · 2022: 193 · 2021: 209 · 2020: 169 · 2019: 162 · 2018: 141 · 2017: 144 · 2016: 152 · 2015: 112 · 2014: 95 · 2013: 31
- FWCI
- 45.68
- Type
- journal article
- Language
- en
- Update notices
- erratum (2013-06-12)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Cancer Institute (T32CA009382, R01CA157490, P01CA120964, P01CA117969, P30CA006516)
- National Institute of General Medical Sciences (R01GM056203)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Keywords
- pancreatic ductal adenocarcinoma, glutamine metabolism, KRAS, tumor metabolic reprogramming, oxaloacetate, NADPH/NADP+ ratio, redox homeostasis, glutamine deprivation, reactive oxygen species, glutathione, tumor growth
- MeSH terms
- Adenocarcinoma, Aspartate Aminotransferases, Citric Acid Cycle, Glutamate Dehydrogenase, Glutamine, Homeostasis, Humans, Ketoglutaric Acids, Oncogenes, Oxidation-Reduction, Pancreatic Neoplasms, Proto-Oncogene Proteins, Oncogene Protein p21(ras), Proto-Oncogene Proteins p21(ras), Reactive Oxygen Species, ras Proteins, Cell Line, Tumor, Cell Proliferation, Metabolic Networks and Pathways
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
